A carregar...
Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
Treatment of BCR-ABL(+) human leukemia has been significantly improved by ABL tyrosine kinase inhibitors (TKIs), but they are not curative for most patients and relapses are frequently associated with BCR-ABL mutations, warranting new targets for improved treatments. We have now demonstrated that pr...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5546432/ https://ncbi.nlm.nih.gov/pubmed/28599273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18216 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|